Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12620001127998
ACTRN12620001127998
Completed
Phase 1

An open-label, randomised, three-arm crossover study to assess the absorption characteristics of different dosing strategies for ManNAc in healthy adult males

niversity of South Australia0 sites12 target enrollmentOctober 30, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsGNE MyopathyMusculoskeletal - Other muscular and skeletal disordersHuman Genetics and Inherited Disorders - Other human genetics and inherited disorders

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
GNE Myopathy
Sponsor
niversity of South Australia
Enrollment
12
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 30, 2020
End Date
December 18, 2020
Last Updated
4 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
niversity of South Australia

Eligibility Criteria

Inclusion Criteria

  • •1\. The participant is a male aged 18\-59 years, inclusive.
  • •2\. Body mass index (BMI) is between 18\-30 kg/m2 with a body weight between 45\-120 kg.
  • •3\. Medically healthy without any clinically significant abnormalities. Health status will be determined by the participant's medical history with specific attention to: (I) drug history identifying any known drug allergies or drug abuse, (II) any chronic use of medication, and (III) a thorough review of body systems (vital signs including an electrocardiogram (ECG), physical examination and clinical laboratory assessment).
  • •4\. Adequate venous access on their left or right arm to allow for collection of multiple blood samples.
  • •5\. The participant is aware of the study procedures and the risks involved, and voluntarily agrees to participate by providing written informed consent.
  • •6\. The participant is willing and able to understand the study procedures and communicate effectively with study personnel.
  • •7\. The participant is willing to be confined to the Clinical Trial Facility for the specified study days.

Exclusion Criteria

  • •1\. History of clinically significant central nervous system (e.g. seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions, or history of any conditions that in the opinion of the Medical Officer, may pose an unacceptable level of risk to either the participants ort study staff, may interfere with the interpretation of safety and/or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of the study compound.
  • •2\. History of hypersensitivity to ManNAc or dietary salt or in the judgment of the Medical Officer, has a condition that places the participant at increased risk for adverse effects.
  • •3\. Consumption of an investigational medication or a new chemical entity within 30 days or 5 half\-lives (whichever is longer) prior to the first dose of study treatment.
  • •4\. The participant has been treated with ManNAc, sialic acid, intravenous immunoglobulin (IVIG), and/or other supplements containing sialic acid (e.g. St. John’s Wort, sialyllactose) less than 120 days prior to administration of the study compound.
  • •5\. Difficulty of refraining from prescription medications and/or over the counter (OTC) products, which in the opinion of the Medical Officer might affect the results of the study or safety of the participant.
  • •6\. Donation of blood or blood products in excess of 550 mL within 12 weeks prior to administration of study medication.
  • •7\. History or current evidence of alcohol abuse and/or difficulty in abstaining from alcohol for 24 h prior to dose administration until the completion of blood sampling in each study period.
  • •8\. History or current evidence of drug abuse, positive urine drug screen during screening, and/or difficulty in abstaining from drugs of abuse throughout the entire study.
  • •9\. Difficulty in abstaining from food and/or beverages that contain caffeine or other xanthines (I.e. coffee, tea, cola, energy drinks and chocolate) for 24 h prior to dose administration until the completion of blood sampling in each study period.
  • •10\. Major surgery within 4 weeks of screening.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
A study to examine the comparative exposure of N-Acetyl-D-Mannosamine Monohydrate (ManNAc) when administered orally as a solution and two novel tablet formulations in healthy adult malesGNE MyopathyHereditary Inclusion Body MyopathyMusculoskeletal - Other muscular and skeletal disorders
ACTRN12623000609651niversity of South Australia6
Completed
Not Applicable
A randomized, open-label, three-way crossover clinical trial to compare safety and pharmacokinetic characteristics after single administration of Carol-F Tab, Advil Liqui-Gels and Brufen Tab 200 mg in healthy male volunteersDiseases of the nervous system
KCT0002017Dong-A University Hospital36
Not yet recruiting
Not Applicable
An investigator initiated study to study how well does a newly developed spirometer by Cipla Ltd. work as compared to the spirometer already available in the market.
CTRI/2019/08/020738Chest Research Foundation
Active, not recruiting
Phase 1
A Phase 3, randomised, open-label, cross-over study to compare HFA vs CFC pMDI formulations of budesonide on methacholine hyper-reactivity in patients with stable, persistent, mild to moderate asthmaAsthmaMedDRA version: 9.1 Level: LLT Classification code 10003553 Term: Asthma
EUCTR2007-006249-42-GBAstraZeneca AB
Active, not recruiting
Not Applicable
AMulti-drug resistant tuberculosisMedDRA version: 14.1Level: PTClassification code 10044755Term: TuberculosisSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2012-005492-13-NLJanssen infectious diseases BVBA